Source link : https://www.newshealth.biz/health-news/discontinuing-specific-meds-linked-to-ms-relapse-risk/
TOPLINE: Discontinuing high-efficacy therapies (HETs) that affect immune cell trafficking such as natalizumab and fingolimod is associated with a significant increased relapse risk in older adults with multiple sclerosis (MS). However, stopping HETs that deplete B cells, such as anti-CD20 therapy, carries no relapse risk. METHODOLOGY: The observational cohort study drew on data on 1620 […]
Author : News Health
Publish date : 2024-03-28 09:55:55
Copyright for syndicated content belongs to the linked Source.